Influence ofSLCO1B1polymorphism on maintenance therapy for childhood leukemia

Autor: Ai Yoshimi, Atsushi Iwabuchi, Masahiro Tsuchida, Emiko Noguchi, Kazutoshi Koike, Hideto Takahashi, Keisuke Kato, Nobutaka Kiyokawa, Enbo Ma, Hiroko Fukushima, Makoto Saito, Takashi Fukushima, Ryoko Suzuki, Chie Kobayashi, Aiko Sakai, Ryoko Nakajima-Yamaguchi, Ryo Sumazaki, Tomohei Nakao
Rok vydání: 2015
Předmět:
Zdroj: Pediatrics International. 57:572-577
ISSN: 1328-8067
DOI: 10.1111/ped.12682
Popis: Background Management of the adverse effects of chemotherapy is essential to improve outcome of children with leukemia. Some genetic polymorphisms can predict treatment-related toxicity, and be used individually in dose modification of 6-mercaptopurine (6-MP) and methotrexate (MTX) in maintenance therapy for childhood acute lymphoblastic leukemia (ALL). We investigated associations between clinical course and candidate gene polymorphisms less evaluated in Japanese patients. Methods Fifty-three children who received maintenance chemotherapy were enrolled in this study. The scheduled dose of oral 6-MP was 40 mg/m2 daily and that of oral MTX was 25 mg/m2 weekly. The doses were adjusted according to white blood cell count (target range, 2.5–3.5 × 109/L) and aspartate aminotransferase and alanine aminotransferase level ( C than in the patients with wild homozygous genotype. The other analyzed polymorphisms were not associated with toxicity, 6-MP, or MTX dose. Conclusions Polymorphism of SLCO1B1 c.521 T > C could be a strong predictor of 6-MP dose reduction in maintenance chemotherapy in childhood ALL.
Databáze: OpenAIRE
Externí odkaz: